Ascentage Pharma Group International Statistics

Total Valuation

Ascentage Pharma Group International has a market cap or net worth of HKD 11.52 billion. The enterprise value is 12.17 billion.

Market Cap	11.52B
Enterprise Value	12.17B

Important Dates

The next estimated earnings date is Wednesday, March 26, 2025.

Earnings Date	Mar 26, 2025
Ex-Dividend Date	n/a

Share Statistics

Ascentage Pharma Group International has 339.25 million shares outstanding. The number of shares has increased by 8.10% in one year.

Current Share Class	n/a
Shares Outstanding	339.25M
Shares Change (YoY)	+8.10%
Shares Change (QoQ)	+2.06%
Owned by Insiders (%)	17.20%
Owned by Institutions (%)	12.44%
Float	191.88M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	10.18
PB Ratio	12.75
P/TBV Ratio	16.19
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-31.44
EV / Sales	12.55
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-15.30

Financial Position

The company has a current ratio of 1.84, with a Debt / Equity ratio of 2.19.

Current Ratio	1.84
Quick Ratio	1.73
Debt / Equity	2.19
Debt / EBITDA	n/a
Debt / FCF	-2.30
Interest Coverage	-4.44

Financial Efficiency

Return on equity (ROE) is -52.38% and return on invested capital (ROIC) is -9.05%.

Return on Equity (ROE)	-52.38%
Return on Assets (ROA)	-7.14%
Return on Invested Capital (ROIC)	-9.05%
Return on Capital Employed (ROCE)	-16.85%
Revenue Per Employee	1.69M
Profits Per Employee	-674,434
Employee Count	583
Asset Turnover	0.30
Inventory Turnover	3.49

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +40.87% in the last 52 weeks. The beta is 1.12, so Ascentage Pharma Group International's price volatility has been higher than the market average.

Beta (5Y)	1.12
52-Week Price Change	+40.87%
50-Day Moving Average	41.31
200-Day Moving Average	32.41
Relative Strength Index (RSI)	33.96
Average Volume (20 Days)	3,812,114

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Ascentage Pharma Group International had revenue of HKD 970.30 million and -387.13 million in losses. Loss per share was -1.33.

Revenue	970.30M
Gross Profit	940.81M
Operating Income	-369.72M
Pretax Income	-397.95M
Net Income	-387.13M
EBITDA	-282.69M
EBIT	-369.72M
Loss Per Share	-1.33

Full Income Statement

Balance Sheet

The company has 1.18 billion in cash and 1.83 billion in debt, giving a net cash position of -644.46 million or -1.90 per share.

Cash & Cash Equivalents	1.18B
Total Debt	1.83B
Net Cash	-644.46M
Net Cash Per Share	-1.90
Equity (Book Value)	834.28M
Book Value Per Share	2.66
Working Capital	965.42M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -765.05 million and capital expenditures -30.79 million, giving a free cash flow of -795.84 million.

Operating Cash Flow	-765.05M
Capital Expenditures	-30.79M
Free Cash Flow	-795.84M
FCF Per Share	-2.35

Full Cash Flow Statement

Margins

Gross margin is 96.96%, with operating and profit margins of -38.10% and -39.90%.

Gross Margin	96.96%
Operating Margin	-38.10%
Pretax Margin	-41.01%
Profit Margin	-39.90%
EBITDA Margin	-29.13%
EBIT Margin	-38.10%
FCF Margin	n/a

Dividends & Yields

Ascentage Pharma Group International does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-8.10%
Shareholder Yield	-8.10%
Earnings Yield	-3.36%
FCF Yield	-6.91%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Ascentage Pharma Group International has an Altman Z-Score of -0.52. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.52
Piotroski F-Score	n/a